Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31672289 | 0.90 | SMN1; SMN2 (0.35) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL25401291 | 0.87 | LMNA (0.38) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL612525 | 0.85 | TSHR (0.38) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL15773974 | 0.82 | — | — | |
| SCHEMBL21294979 | 0.80 | LMNA (0.38) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL797619 | 0.80 | — | — | |
| SCHEMBL18574556 | 0.80 | — | — | |
| SCHEMBL9768351 | 0.77 | — | — | |
| SCHEMBL2697437 | 0.76 | — | — | |
| SCHEMBL14513794 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113493308-A | High-reflection glass glaze capable of improving conversion rate of solar cell | 广东奥迪博士实业有限公司 | 2021-10-12 | — | — | CN | claimed |
| US-11331274-B2 | Milrinone controlled-release formulation | Baker Heart and Diabetes Institute (AU) | 2022-05-17 | — | — | US | disclosed |
| CN-113493308-A | High-reflection glass glaze capable of improving conversion rate of solar cell | 广东奥迪博士实业有限公司 | 2021-10-12 | — | — | CN | disclosed |
| EP-3718546-A1 | CONTROLLED-RELEASE FORMULATION | Cardiora Pty Ltd (AU) | 2020-10-07 | — | — | EP | disclosed |
| US-10736853-B2 | Milrinone controlled-release formulation | CARDIORA PTY LTD. (AU) | 2020-08-11 | — | — | US | disclosed |
| US-20200146992-A1 | MILRINONE CONTROLLED-RELEASE FORMULATION | CARDIORA PTY LTD. (AU) | 2020-05-14 | — | — | US | disclosed |
| US-20200101053-A1 | METHOD OF TREATING HEART FAILURE WITH PRESERVED EJECTION FRACTION BY ADMINISTERING MILRINONE | CARDIORA PTY LTD (AU) | 2020-04-02 | — | — | US | disclosed |
| EP-3236963-B1 | METHOD OF TREATMENT | CARDIORA PTY LTD (AU) | 2020-01-29 | — | — | EP | disclosed |
| US-10537527-B2 | — | — | 2020-01-21 | — | — | US | disclosed |
| US-20190091156-A1 | MILRINONE CONTROLLED-RELEASE FORMULATION | Baker Heart and Diabetes Institute (AU) | 2019-03-28 | — | — | US | disclosed |
| US-10137093-B2 | Milrinone controlled-release formulation | CARDIORA PTY LTD. (AU) | 2018-11-27 | — | — | US | disclosed |
| US-20180325826-A1 | CONTROLLED-RELEASE FORMULATION | Baker Heart and Diabetes Institute (AU) | 2018-11-15 | — | — | US | disclosed |
| US-20170348292-A1 | METHOD OF TREATMENT | Baker Heart and Diabetes Institute (AU) | 2017-12-07 | — | — | US | disclosed |
| EP-3236963-A1 | METHOD OF TREATMENT | Cardiora Pty Ltd (AU) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016101024-A1 | METHOD OF TREATMENT | BAKER IDI HEART & DIABETES INSTITUTE HOLDINGS LIMITED (AU) | 2016-06-30 | — | — | WO | disclosed |
| US-20140328908-A1 | CONTROLLED-RELEASE FORMULATION | BAKER IDI HEART & DIABETES INSTITUTE HOLDINGS LIMITED (AU) | 2014-11-06 | — | — | US | disclosed |
| EP-2744496-A1 | CONTROLLED-RELEASE FORMULATION | Baker IDI Heart and Diabetes Institute Holdings Ltd (AU) | 2014-06-25 | — | — | EP | disclosed |
| WO-2013023250-A1 | CONTROLLED-RELEASE FORMULATION | BAKER IDI HEART & DIABETES INSTITUTE HOLDINGS LIMITED (AU) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10537527-B2 | — | TNNC1, TNNI3, TNNT2 | TSHR 2926/4885MAPK1 4266/4885ALDH1A1 817/4885 |
| US-20190091156-A1 | MILRINONE CONTROLLED-RELEASE FORMULATION | SIRT5, TNNI3, PROC | TSHR 2339/4885MAPK1 3376/4885ALDH1A1 1396/4885 |
| US-11331274-B2 | Milrinone controlled-release formulation | SIRT5, TNNI3, PROC | TSHR 2339/4885MAPK1 3376/4885ALDH1A1 1396/4885 |
| US-10736853-B2 | Milrinone controlled-release formulation | SIRT5, TNNI3, PROC | TSHR 2339/4885MAPK1 3376/4885ALDH1A1 1396/4885 |
| US-20170348292-A1 | METHOD OF TREATMENT | TNNI3, NPPA, TNNT2 | TSHR 1660/4885MAPK1 3954/4885ALDH1A1 1581/4885 |
| US-20140328908-A1 | CONTROLLED-RELEASE FORMULATION | TNNC1, CYP3A5, TNNI3 | TSHR 2263/4885MAPK1 4418/4885ALDH1A1 1076/4885 |
| US-20200146992-A1 | MILRINONE CONTROLLED-RELEASE FORMULATION | SIRT5, TNNI3, PROC | TSHR 2339/4885MAPK1 3376/4885ALDH1A1 1396/4885 |
| US-20200101053-A1 | METHOD OF TREATING HEART FAILURE WITH PRESERVED EJECTION FRACTION BY ADMINISTERING MILRINONE | TNNI3, NPPA, TNNT2 | TSHR 3051/4885MAPK1 3485/4885ALDH1A1 836/4885 |
| US-20180325826-A1 | CONTROLLED-RELEASE FORMULATION | TNNC1, CYP3A5, TNNI3 | TSHR 2263/4885MAPK1 4418/4885ALDH1A1 1076/4885 |
| US-10137093-B2 | Milrinone controlled-release formulation | SIRT5, TNNI3, PROC | TSHR 2339/4885MAPK1 3376/4885ALDH1A1 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.